Treatment options for relapsed small-cell lung cancer

  title={Treatment options for relapsed small-cell lung cancer},
  author={H. Azim and A. Ganti},
  journal={Anti-Cancer Drugs},
  • H. Azim, A. Ganti
  • Published 2007
  • Medicine
  • Anti-Cancer Drugs
  • Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5… CONTINUE READING
    15 Citations
    Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer.
    • J. Singh, Suaib Luqman, Abha Meena
    • Medicine
    • Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
    • 2020
    • 1
    Clinical development of new formulations of cytotoxics in solid tumors
    • 7
    Dual or multi-targeting inhibitors: The next generation anticancer agents.
    • 56


    VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
    • 248
    A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
    • C. Rudin, G. Otterson, +6 authors E. Vokes
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2002
    • 118
    Phase II study of imatinib in patients with small cell lung cancer.
    • 172
    • PDF
    Small cell lung cancer.
    • 1,129
    • PDF
    Chemotherapy versus best supportive care for extensive small cell lung cancer.
    • 76
    • PDF
    Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
    • 44
    Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
    • H. Groen, E. Fokkema, +4 authors E. Smit
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1999
    • 102
    Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
    • 130